To fight cancer by a newly developed substance shredding carcinogenic aurora proteins: This is the aim of a new study by scientists at universities in Würzburg and Frankfurt. Dr. Sandy Pernitzsch

Researchers at the universities of Würzburg and Frankfurt have developed a new compound for treating cancer. It destroys a protein that triggers its development.
The villain in this drama has a pretty name: Aurora – Latin for dawn. In the world of biochemistry, however, Aurora (more precisely: Aurora-A kinase) stands for a protein that causes extensive damage. There, it has been known for a long time that Aurora often causes cancer. It triggers the development of leukemias and many pediatric cancers, such as neuroblastomas.

The physical structures of cancer cells are disrupted by a web forming inside of the cells – which activates their self destruction mechanism. © MPI-P

According to the Federal Statistical Office of Germany, cancer is one of the most frequent causes of death, accounting for almost 25% of all deaths cases. Chemotherapy is often used as a treatment, but also brings side effects for healthy organs. Scientists around David Ng, group leader at the Max Planck Institute for Polymer Research, are now trying to take a completely different approach: By means of targeted and localized disruption of the cancer cells’ structure, its self-destruction mechanism can be activated. In laboratory experiments, they have already demonstrated initial successes.

Images of macrophages (red) in which the active substance (green) is distributed. On the left, the active substance heparin is shown, on the right hyaluronic acid. Hala Al Khoury / Uni Halle

New coatings on implants could help make them more compatible. Researchers at the Martin Luther University Halle-Wittenberg (MLU) have developed a new method of applying anti-inflammatory substances to implants in order to inhibit undesirable inflammatory reactions in the body. Their study was recently published in the "International Journal of Molecular Sciences".

Illustration_1: Stroke leads to a reduction of VEGFD levels, loss of dendrites, brain damage, and impaired motor functions. As research on a mouse model has shown, VEGFD-based therapies can prevent structural disintegration, thereby facilitating functional recovery. Heidelberg University

Protecting nerve cells from losing their characteristic extensions, the dendrites, can reduce brain damage after a stroke. Neurobiologists from Heidelberg University have demonstrated this by means of research on a mouse model. The team, led by Prof. Dr Hilmar Bading in cooperation with Junior Professor Dr Daniela Mauceri, is investigating the protection of neuronal architecture to develop new approaches to treating neurodegenerative diseases. The current research findings were published in the journal “Proceedings of the National Academy of Sciences”.